BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32066715)

  • 1. A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping.
    Fabbri C; Kasper S; Kautzky A; Zohar J; Souery D; Montgomery S; Albani D; Forloni G; Ferentinos P; Rujescu D; Mendlewicz J; Uher R; Lewis CM; Serretti A
    Transl Psychiatry; 2020 Feb; 10(1):50. PubMed ID: 32066715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples.
    Fabbri C; Kasper S; Kautzky A; Bartova L; Dold M; Zohar J; Souery D; Montgomery S; Albani D; Raimondi I; Dikeos D; Rujescu D; Uher R; Lewis CM; Mendlewicz J; Serretti A
    Br J Psychiatry; 2019 Jan; 214(1):36-41. PubMed ID: 30468137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance.
    Fabbri C; Corponi F; Albani D; Raimondi I; Forloni G; Schruers K; Kasper S; Kautzky A; Zohar J; Souery D; Montgomery S; Cristalli CP; Mantovani V; Mendlewicz J; Serretti A
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():203-210. PubMed ID: 28989100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polygenic risk scores of lithium response and treatment resistance in major depressive disorder.
    Xiong Y; Karlsson R; Song J; Kowalec K; Rück C; Sigström R; Jonsson L; Clements CC; Andersson E; Boberg J; Lewis CM; Sullivan PF; Landén M; Lu Y
    Transl Psychiatry; 2023 Sep; 13(1):301. PubMed ID: 37770441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts.
    Fabbri C; Hagenaars SP; John C; Williams AT; Shrine N; Moles L; Hanscombe KB; Serretti A; Shepherd DJ; Free RC; Wain LV; Tobin MD; Lewis CM
    Mol Psychiatry; 2021 Jul; 26(7):3363-3373. PubMed ID: 33753889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder.
    Fanelli G; Benedetti F; Kasper S; Zohar J; Souery D; Montgomery S; Albani D; Forloni G; Ferentinos P; Rujescu D; Mendlewicz J; Serretti A; Fabbri C
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jun; 108():110170. PubMed ID: 33181205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of N-methyl-D-aspartate receptor gene (GRIN2B) variants as predictors of treatment-resistant major depression.
    Zhang C; Li Z; Wu Z; Chen J; Wang Z; Peng D; Hong W; Yuan C; Wang Z; Yu S; Xu Y; Xu L; Xiao Z; Fang Y
    Psychopharmacology (Berl); 2014 Feb; 231(4):685-93. PubMed ID: 24114429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?
    Dodd S; Bauer M; Carvalho AF; Eyre H; Fava M; Kasper S; Kennedy SH; Khoo JP; Lopez Jaramillo C; Malhi GS; McIntyre RS; Mitchell PB; Castro AMP; Ratheesh A; Severus E; Suppes T; Trivedi MH; Thase ME; Yatham LN; Young AH; Berk M
    World J Biol Psychiatry; 2021 Sep; 22(7):483-494. PubMed ID: 33289425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exome-wide association study of treatment-resistant depression suggests novel treatment targets.
    Shah SB; Peddada TN; Song C; Mensah M; Sung H; Yavi M; Yuan P; Zarate CA; Mickey BJ; Burmeister M; Akula N; McMahon FJ
    Sci Rep; 2023 Aug; 13(1):12467. PubMed ID: 37528149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of GRIK4 gene in treatment-resistant depression.
    Milanesi E; Bonvicini C; Congiu C; Bortolomasi M; Gainelli G; Gennarelli M; Minelli A
    Genet Res (Camb); 2015 Jul; 97():e14. PubMed ID: 26139080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression.
    Olgiati P; Serretti A; Souery D; Dold M; Kasper S; Montgomery S; Zohar J; Mendlewicz J
    J Affect Disord; 2018 Feb; 227():777-786. PubMed ID: 29254066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptome-wide association study of treatment-resistant depression and depression subtypes for drug repurposing.
    Fabbri C; Pain O; Hagenaars SP; Lewis CM; Serretti A
    Neuropsychopharmacology; 2021 Sep; 46(10):1821-1829. PubMed ID: 34158615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Evaluation of the Clinical and Economic Burden Among Older Adult Medicare-Covered Beneficiaries With Treatment-Resistant Depression.
    Benson C; Szukis H; Sheehan JJ; Alphs L; Yuce H
    Am J Geriatr Psychiatry; 2020 Mar; 28(3):350-362. PubMed ID: 31735488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance.
    Fabbri C; Crisafulli C; Calati R; Albani D; Forloni G; Calabrò M; Martines R; Kasper S; Zohar J; Juven-Wetzler A; Souery D; Montgomery S; Mendlewicz J; Serretti A
    Eur Arch Psychiatry Clin Neurosci; 2017 Dec; 267(8):723-735. PubMed ID: 28260126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life burden associated with treatment-resistant depression in UK patients: Quantitative results from a mixed-methods non-interventional study.
    Rathod S; Denee T; Eva J; Kerr C; Jacobsen N; Desai M; Baldock L; Young AH
    J Affect Disord; 2022 Mar; 300():551-562. PubMed ID: 34965398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic impact of treatment-resistant depression: A retrospective observational study.
    Pérez-Sola V; Roca M; Alonso J; Gabilondo A; Hernando T; Sicras-Mainar A; Sicras-Navarro A; Herrera B; Vieta E
    J Affect Disord; 2021 Dec; 295():578-586. PubMed ID: 34509073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic burden of treatment-resistant depression among veterans in the United States.
    Szukis H; Joshi K; Huang A; Amos TB; Wang L; Benson CJ
    Curr Med Res Opin; 2021 Aug; 37(8):1393-1401. PubMed ID: 33879005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study.
    Fabbri C; Kasper S; Zohar J; Souery D; Montgomery S; Albani D; Forloni G; Ferentinos P; Rujescu D; Mendlewicz J; De Ronchi D; Riva MA; Lewis CM; Serretti A
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jan; 104():110050. PubMed ID: 32738352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FAS -670A>G genetic polymorphism Is associated with Treatment Resistant Depression.
    Santos M; Carvalho S; Lima L; Mota-Pereira J; Pimentel P; Maia D; Correia D; Gomes S; Cruz A; Medeiros R
    J Affect Disord; 2015 Oct; 185():164-9. PubMed ID: 26186532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current treatments used in clinical practice for major depressive disorder and treatment resistant depression in England: A retrospective database study.
    Denee T; Kerr C; Ming T; Wood R; Tritton T; Middleton-Dalby C; Massey O; Desai M
    J Psychiatr Res; 2021 Jul; 139():172-178. PubMed ID: 34077893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.